To determine responses to Ibrutinib (PCI-32765) alone as well as Ibrutinib/S-Mepazine co-treatment on ABC DLBCL cells, we used a set of four well-characterized cell lines with distinct genetic lesions in the BCR signaling pathway. The gene discussed is BCR; the disease is aneurysmal bone cyst.